E156 Micro-Paper · Africa Clinical Trials

Neonatal Mortality Gap

Sub-Saharan Africa accounts for 43% of global neonatal deaths, yet neonatal tria...

Africa Trials
1,252
US Trials
10,923
Gap Ratio
9x
Gini
0.732
Africa hosted 1,252 neonatal trials versus 10,923 in the United States, a 9-fold disparity in research investment.
Neonatal Mortality Gap Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.711
Neonatal Mortality Gap by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
Regional Comparison Africa US Europe 0 5000 10000
No data
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
Research Profile Volume Growth Phase3 Complete Diversity Equity
Enrollment Distribution Africa Reference 2000 4000 6000
No data
Why It Matters

Sub-Saharan Africa accounts for 43% of global neonatal deaths, yet neonatal trial investment is a fraction of what's needed to test context-appropriate interventions for low-resource settings.

In the burden-versus-investment landscape of African health research, does the distribution of neonatal trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation. Africa hosted 1,252 neonatal trials (5.2% of its portfolio) compared to 10,923 in the United States, yielding a 0.0-fold disparity in per-population investment. Sensitivity analysis using Gini coefficient (0.732) confirmed the inequality finding and bootstrap resampling showed stable estimates. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.
Question

In the burden-versus-investment landscape of African health research, does the distribution of neonatal trials across African nations reveal a systematic research gap?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation.

Robustness

Africa hosted 1,252 neonatal trials (5.

Interpretation

2% of its portfolio) compared to 10,923 in the United States, yielding a 0.

Boundary

0-fold disparity in per-population investment.

Extra

Sensitivity analysis using Gini coefficient (0.

Extra

732) confirmed the inequality finding and bootstrap resampling showed stable estimates.

Extra

These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.

Extra

Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.